Stand Up To Cancer (SU2C) is an initiative to improve the participation of Black, Indigenous, and People of Color (BIPOC) in cancer clinical trials. The SU2C team consists of doctors and scientists from four New York City institutions specializing in social science and clinical research.
This team is a central component of SU2C’s Health Equity Initiative. In January of 2020, they announced that the initiative would require all future SU2C-supported research grants to address the recruitment and retention of BIPOC patients in cancer clinical trials.
The Health Equity Committee is chaired by Dr. Edith Perez, MD, professor of medicine at the Mayo Clinic and Chief Medical Officer at Bolt Biotherapeutics. SU2C’s Health Equity Breakthrough Team is due to receive funding of $6 million in support of its efforts.
The SU2C team will focus on three areas: community organization, training scientists and doctors to better understand how life circumstances affect health outcomes of certain communities, and exploring ways to better inform underrepresented patients about clinical trials.
The diverse team of clinical cancer specialists and experts in social science will help bring forth diversity in clinical trials that work to eradicate cancer in the greater community of patients. As for SU2C’s ongoing Health Equity Initiative, it will continue to fund awareness campaigns and research centered on critical issues associated with cancer clinical trial disparities .
Source: Increasing diversity in clinical trials the focus of new stand up to cancer team. (2021, March 23). EurekAlert! https://www.eurekalert.org/pub_releases/2021-03/sutc-idi032221.php